PR Newswire·Nov 12, 2026, 4:10 PM ET

Atrium Therapeutics Reports Third Quarter 2026 Financial Results

RNA

Atrium Therapeutics dosed the first patient in the Corventis Phase 1/2 clinical trial for ATR 1072 in PRKAG2 syndrome.
Nonclinical data demonstrated that ATR 1072 reversed cardiac glycogen accumulation & improved disease features in mouse models.
The company closed a $50 million private placement with institutional investors to extend its cash runway through 2028.
Pro-forma cash balance as of September 30, 2026, was $293.6 million, including the $15 million Bristol Myers Squibb milestone payment & private placement proceeds.
Third quarter 2026 collaboration revenue was $15.3 million, primarily from the Bristol Myers Squibb research agreement.
Research & development expenses for the third quarter were $13.8 million, driven by Corventis trial activities & ATR 1086 development.
General & administrative expenses totaled $8.2 million for the third quarter of 2026.
Atrium expects to report initial proof-of-concept data from the Corventis trial in the second half of 2027.
The company plans to file an IND application for ATR 1086 (PLN cardiomyopathy) & advance two undisclosed rare cardiomyopathy programs in 2027.
The Corventis trial is designed to evaluate safety, pharmacokinetics, & efficacy of ATR 1072 in approximately 37 participants across two study parts.
PRKAG2 syndrome is a rare genetic cardiomyopathy caused by PRKAG2 gene variants leading to abnormal cardiac glycogen accumulation.
PLN cardiomyopathy is a progressive cardiac disease caused by PLN mutations that disrupt calcium pump processes & increase heart failure risk.

Company: Atrium Therapeutics
Keywords: Atrium Therapeutics